Pipeline

Product Candidate

Preclinical

Phase 1

Phase 2

PB-2070%

Multi-Target. Healthspan/Lifespan extension.
Phase: Preclinical

PB-007-30%

Lifespan extension
Phase: Preclinical

PB-007-10%

Targeting TYK2, JAK1
Phase: Preclinical